Next Article in Journal
Specific Protocols of Controlled Ovarian Stimulation for Oocyte Cryopreservation in Breast Cancer Patients
Previous Article in Journal
Reducing Postsurgical Exudate in Breast Cancer Patients by Using San Huang Decoction to Ameliorate Inflammatory Status: A Prospective Clinical Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 6
10.3747/co.25.4069
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response

by
S. Sud
1,*,
C. O’Callaghan
2,
C. Jonker
1,
C. Karapetis
3,
T. Price
4,
N. Tebbutt
5,
J. Shapiro
6,
G. Van Hazel
7,
N. Pavlakis
8,
P. Gibbs
9,
M. Jeffrey
10,
L. Siu
11,
S. Gill
12,
R. Wong
13,
D. Jonker
1,
D. Tu
2 and
R. Goodwin
1
1
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada
2
NCIC Clinical Trials Group, Queen’s University, Kingston, ON K7L 3N6, Canada
3
Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA 5042, Australia
4
The Queen Elizabeth and University of Adelaide, Adelaide, SA 5005, Australia
5
Austin Health, Melbourne, VIC 3084, Australia
6
Department of Medical Oncology, Monash University, Melbourne, VIC 3084, Australia
7
University of Western Australia, Perth, WA 6009, Australia
8
Royal North Shore Hospital, Northern Clinical School, University of Sydney, St. Leonards, NSW 2006, Australia
9
Royal Melbourne Hospital, Melbourne, VIC 3050, Australia
10
Oncology Service, Christchurch Hospital, Christchurch 8011, New Zealand
11
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5S, Canada
12
University of British Columbia, BC Cancer, Vancouver, BC V5Z 1L3, Canada
13
Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(6), 516-526; https://doi.org/10.3747/co.25.4069
Submission received: 5 September 2018 / Revised: 11 October 2018 / Accepted: 3 November 2018 / Published: 1 December 2018

Abstract

Background Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Methods Using data from the Canadian Cancer Trials Group co.17 study [cetuximab vs. best supportive care (bsc)], we coded baseline htn and use of anti-htn medications, including bbs, for 572 patients. The chi-square test was used to assess the associations between those variables and baseline characteristics. Cox regression models were used for univariate and multivariate analyses of os and pfs by htn diagnosis and bb use. Results Baseline htn, bb use, and anti-htn medication use were not found to be prognostic for improved os. Baseline htn and bb use were not significant predictors of cetuximab benefit. Conclusions In chemorefractory mcrc, neither baseline htn nor bb use is a significant prognostic factor. Baseline htn and bb use are not predictive of cetuximab benefit. Further investigation to determine whether baseline htn or bb use have a similarly insignificant impact on prognosis in patients receiving earlier lines of treatment remains warranted.
Keywords: colorectal cancer; hypertension colorectal cancer; hypertension

Share and Cite

MDPI and ACS Style

Sud, S.; O’Callaghan, C.; Jonker, C.; Karapetis, C.; Price, T.; Tebbutt, N.; Shapiro, J.; Van Hazel, G.; Pavlakis, N.; Gibbs, P.; et al. Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Curr. Oncol. 2018, 25, 516-526. https://doi.org/10.3747/co.25.4069

AMA Style

Sud S, O’Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, et al. Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Current Oncology. 2018; 25(6):516-526. https://doi.org/10.3747/co.25.4069

Chicago/Turabian Style

Sud, S., C. O’Callaghan, C. Jonker, C. Karapetis, T. Price, N. Tebbutt, J. Shapiro, G. Van Hazel, N. Pavlakis, P. Gibbs, and et al. 2018. "Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response" Current Oncology 25, no. 6: 516-526. https://doi.org/10.3747/co.25.4069

APA Style

Sud, S., O’Callaghan, C., Jonker, C., Karapetis, C., Price, T., Tebbutt, N., Shapiro, J., Van Hazel, G., Pavlakis, N., Gibbs, P., Jeffrey, M., Siu, L., Gill, S., Wong, R., Jonker, D., Tu, D., & Goodwin, R. (2018). Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Current Oncology, 25(6), 516-526. https://doi.org/10.3747/co.25.4069

Article Metrics

Back to TopTop